| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units, Pediatric | 32 | 2021 | 476 | 3.240 |
Why?
|
| Heart Defects, Congenital | 29 | 2023 | 1796 | 2.760 |
Why?
|
| Critical Care | 17 | 2023 | 794 | 2.570 |
Why?
|
| Cardiopulmonary Bypass | 14 | 2021 | 384 | 2.290 |
Why?
|
| Shock, Septic | 20 | 2018 | 188 | 2.070 |
Why?
|
| Heart Diseases | 12 | 2019 | 722 | 1.800 |
Why?
|
| Cardiac Surgical Procedures | 17 | 2024 | 1149 | 1.690 |
Why?
|
| Respiratory Syncytial Virus Infections | 9 | 2019 | 443 | 1.320 |
Why?
|
| Infant | 70 | 2023 | 13994 | 1.240 |
Why?
|
| Critical Illness | 10 | 2022 | 734 | 1.240 |
Why?
|
| Heart Arrest | 7 | 2019 | 381 | 1.220 |
Why?
|
| Diuretics | 3 | 2017 | 170 | 1.200 |
Why?
|
| Clinical Deterioration | 2 | 2017 | 12 | 1.160 |
Why?
|
| Multiple Organ Failure | 6 | 2022 | 176 | 1.150 |
Why?
|
| Diuresis | 2 | 2017 | 63 | 1.140 |
Why?
|
| Hospital Rapid Response Team | 2 | 2017 | 38 | 1.110 |
Why?
|
| Hospitals, Pediatric | 8 | 2023 | 796 | 1.090 |
Why?
|
| Troponin I | 6 | 2006 | 131 | 1.040 |
Why?
|
| Morbidity | 5 | 2016 | 397 | 1.030 |
Why?
|
| Cardiopulmonary Resuscitation | 9 | 2019 | 347 | 0.990 |
Why?
|
| Consensus | 5 | 2017 | 1113 | 0.920 |
Why?
|
| Oxygen | 4 | 2012 | 786 | 0.900 |
Why?
|
| Hemodynamics | 8 | 2022 | 941 | 0.900 |
Why?
|
| Child | 72 | 2023 | 30558 | 0.840 |
Why?
|
| Hypoplastic Left Heart Syndrome | 5 | 2021 | 253 | 0.830 |
Why?
|
| Child, Preschool | 55 | 2020 | 17071 | 0.790 |
Why?
|
| Length of Stay | 10 | 2019 | 1995 | 0.780 |
Why?
|
| Infant, Newborn | 33 | 2023 | 8603 | 0.770 |
Why?
|
| Extracorporeal Membrane Oxygenation | 5 | 2018 | 640 | 0.760 |
Why?
|
| Coronary Care Units | 2 | 2018 | 38 | 0.740 |
Why?
|
| Nitric Oxide | 3 | 2014 | 657 | 0.710 |
Why?
|
| Natriuretic Peptide, Brain | 6 | 2017 | 326 | 0.710 |
Why?
|
| Respiratory Syncytial Viruses | 4 | 2017 | 169 | 0.710 |
Why?
|
| Shock | 2 | 2013 | 93 | 0.700 |
Why?
|
| Monitoring, Physiologic | 7 | 2022 | 515 | 0.700 |
Why?
|
| Heart Failure | 8 | 2020 | 2330 | 0.680 |
Why?
|
| Intensive Care Units | 6 | 2023 | 729 | 0.660 |
Why?
|
| Postoperative Complications | 10 | 2020 | 5674 | 0.660 |
Why?
|
| Heart-Assist Devices | 5 | 2019 | 1047 | 0.640 |
Why?
|
| Acute Kidney Injury | 6 | 2017 | 758 | 0.640 |
Why?
|
| Epinephrine | 3 | 2018 | 249 | 0.630 |
Why?
|
| Vasodilator Agents | 3 | 2018 | 231 | 0.620 |
Why?
|
| Humans | 129 | 2024 | 270637 | 0.600 |
Why?
|
| Metolazone | 1 | 2017 | 5 | 0.600 |
Why?
|
| Syringes | 1 | 2017 | 39 | 0.590 |
Why?
|
| Evidence-Based Medicine | 4 | 2022 | 1027 | 0.580 |
Why?
|
| Spironolactone | 1 | 2017 | 23 | 0.570 |
Why?
|
| Pediatrics | 9 | 2021 | 1194 | 0.570 |
Why?
|
| Potassium | 2 | 2022 | 327 | 0.570 |
Why?
|
| Chlorothiazide | 1 | 2016 | 12 | 0.560 |
Why?
|
| Nephrons | 1 | 2016 | 42 | 0.550 |
Why?
|
| Cardiac Output | 4 | 2022 | 194 | 0.550 |
Why?
|
| Sepsis | 6 | 2017 | 673 | 0.540 |
Why?
|
| Truth Disclosure | 1 | 2018 | 178 | 0.540 |
Why?
|
| Emergency Treatment | 1 | 2017 | 105 | 0.530 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 14 | 0.520 |
Why?
|
| Alprostadil | 1 | 2015 | 36 | 0.510 |
Why?
|
| Respiration, Artificial | 10 | 2019 | 584 | 0.510 |
Why?
|
| Heart Rate | 2 | 2017 | 743 | 0.500 |
Why?
|
| Pneumonia, Ventilator-Associated | 2 | 2016 | 50 | 0.500 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2020 | 562 | 0.480 |
Why?
|
| Troponin | 2 | 2012 | 85 | 0.480 |
Why?
|
| Severity of Illness Index | 7 | 2021 | 4391 | 0.470 |
Why?
|
| Weight Gain | 1 | 2017 | 462 | 0.470 |
Why?
|
| Postoperative Care | 6 | 2019 | 726 | 0.470 |
Why?
|
| Premedication | 2 | 2005 | 132 | 0.470 |
Why?
|
| Hypotension | 3 | 2021 | 225 | 0.460 |
Why?
|
| Tetralogy of Fallot | 2 | 2012 | 163 | 0.460 |
Why?
|
| Water | 1 | 2016 | 386 | 0.450 |
Why?
|
| Blood Pressure | 3 | 2019 | 1555 | 0.450 |
Why?
|
| Pain, Postoperative | 2 | 2024 | 662 | 0.450 |
Why?
|
| Biomarkers | 20 | 2018 | 5048 | 0.440 |
Why?
|
| Antiviral Agents | 5 | 2019 | 1243 | 0.440 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2014 | 316 | 0.440 |
Why?
|
| Male | 68 | 2022 | 128446 | 0.440 |
Why?
|
| Furosemide | 3 | 2017 | 42 | 0.430 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2013 | 49 | 0.430 |
Why?
|
| Ventricular Fibrillation | 2 | 2003 | 57 | 0.430 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2014 | 626 | 0.400 |
Why?
|
| Female | 68 | 2022 | 148834 | 0.400 |
Why?
|
| Palivizumab | 6 | 2019 | 62 | 0.400 |
Why?
|
| Heart Transplantation | 4 | 2010 | 904 | 0.380 |
Why?
|
| Norwood Procedures | 2 | 2023 | 100 | 0.380 |
Why?
|
| Vascular Resistance | 1 | 2012 | 210 | 0.380 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2024 | 453 | 0.380 |
Why?
|
| Heart Injuries | 1 | 2011 | 51 | 0.380 |
Why?
|
| Myocardial Reperfusion Injury | 1 | 2012 | 160 | 0.380 |
Why?
|
| Hypertension, Pulmonary | 3 | 2018 | 463 | 0.370 |
Why?
|
| Down Syndrome | 1 | 2013 | 227 | 0.360 |
Why?
|
| Retrospective Studies | 27 | 2023 | 39954 | 0.350 |
Why?
|
| Linear Models | 3 | 2017 | 1092 | 0.340 |
Why?
|
| Postoperative Period | 5 | 2017 | 666 | 0.340 |
Why?
|
| Quality Assurance, Health Care | 3 | 2008 | 593 | 0.330 |
Why?
|
| Cardiovascular Diseases | 3 | 2022 | 2213 | 0.330 |
Why?
|
| Risk Factors | 17 | 2020 | 17849 | 0.320 |
Why?
|
| Hospitalization | 4 | 2019 | 2169 | 0.320 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2009 | 46 | 0.320 |
Why?
|
| Dexamethasone | 2 | 2005 | 1525 | 0.320 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 2 | 2001 | 76 | 0.310 |
Why?
|
| Acetaminophen | 2 | 2019 | 121 | 0.300 |
Why?
|
| Matrix Metalloproteinase 8 | 6 | 2017 | 16 | 0.300 |
Why?
|
| Vasodilation | 1 | 2009 | 212 | 0.300 |
Why?
|
| Glucocorticoids | 3 | 2015 | 610 | 0.300 |
Why?
|
| Societies, Medical | 6 | 2023 | 1323 | 0.300 |
Why?
|
| Databases, Factual | 3 | 2008 | 2258 | 0.290 |
Why?
|
| Hematologic Diseases | 1 | 2008 | 255 | 0.280 |
Why?
|
| Steroids | 1 | 2009 | 372 | 0.280 |
Why?
|
| Prospective Studies | 18 | 2021 | 13406 | 0.280 |
Why?
|
| Hydrocortisone | 3 | 2018 | 401 | 0.270 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 1467 | 0.270 |
Why?
|
| Risk Assessment | 12 | 2020 | 6765 | 0.270 |
Why?
|
| Near Drowning | 1 | 2006 | 26 | 0.260 |
Why?
|
| Biological Transport | 3 | 2011 | 630 | 0.260 |
Why?
|
| Obesity | 1 | 2017 | 2888 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 3427 | 0.240 |
Why?
|
| Organ Dysfunction Scores | 2 | 2022 | 69 | 0.240 |
Why?
|
| Carbon Dioxide | 2 | 2023 | 327 | 0.240 |
Why?
|
| HSP70 Heat-Shock Proteins | 5 | 2017 | 159 | 0.240 |
Why?
|
| Granzymes | 4 | 2017 | 94 | 0.240 |
Why?
|
| Methylprednisolone | 1 | 2005 | 200 | 0.240 |
Why?
|
| Natriuretic Agents | 3 | 2017 | 32 | 0.240 |
Why?
|
| Treatment Outcome | 20 | 2024 | 33840 | 0.230 |
Why?
|
| Texas | 7 | 2017 | 6445 | 0.230 |
Why?
|
| Transcriptome | 4 | 2021 | 1960 | 0.230 |
Why?
|
| Cardiotonic Agents | 2 | 2017 | 153 | 0.230 |
Why?
|
| Respiratory Insufficiency | 2 | 2007 | 342 | 0.230 |
Why?
|
| Drug Therapy, Combination | 3 | 2017 | 2343 | 0.230 |
Why?
|
| Respiratory Syncytial Virus, Human | 2 | 2019 | 223 | 0.230 |
Why?
|
| Positive-Pressure Respiration | 1 | 2004 | 122 | 0.220 |
Why?
|
| Tissue and Organ Procurement | 1 | 2006 | 243 | 0.220 |
Why?
|
| Age Factors | 10 | 2020 | 5436 | 0.220 |
Why?
|
| Saline Solution, Hypertonic | 1 | 2003 | 26 | 0.220 |
Why?
|
| Ventricular Dysfunction | 1 | 2003 | 33 | 0.220 |
Why?
|
| Models, Theoretical | 4 | 2015 | 799 | 0.210 |
Why?
|
| Neonatology | 1 | 2023 | 47 | 0.210 |
Why?
|
| Peer Review | 1 | 2023 | 82 | 0.210 |
Why?
|
| Hemodynamic Monitoring | 1 | 2022 | 12 | 0.210 |
Why?
|
| Myocardium | 1 | 2008 | 1180 | 0.210 |
Why?
|
| Chemokine CCL3 | 3 | 2017 | 64 | 0.210 |
Why?
|
| Interleukin-8 | 4 | 2017 | 527 | 0.200 |
Why?
|
| United States | 15 | 2023 | 15813 | 0.200 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 4315 | 0.200 |
Why?
|
| Intubation, Intratracheal | 2 | 2023 | 473 | 0.200 |
Why?
|
| Guideline Adherence | 2 | 2018 | 625 | 0.200 |
Why?
|
| Clinical Protocols | 1 | 2004 | 476 | 0.200 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2017 | 5053 | 0.200 |
Why?
|
| Tissue Donors | 1 | 2006 | 819 | 0.200 |
Why?
|
| Dietary Supplements | 2 | 2018 | 550 | 0.190 |
Why?
|
| Intracranial Hypertension | 1 | 2003 | 125 | 0.190 |
Why?
|
| Mentoring | 1 | 2023 | 105 | 0.190 |
Why?
|
| Airway Obstruction | 1 | 2004 | 274 | 0.190 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2003 | 164 | 0.190 |
Why?
|
| Emergency Medical Services | 1 | 2006 | 469 | 0.180 |
Why?
|
| Infant, Premature | 3 | 2019 | 832 | 0.180 |
Why?
|
| Palliative Care | 3 | 2014 | 2176 | 0.180 |
Why?
|
| California | 3 | 2006 | 209 | 0.180 |
Why?
|
| Time Factors | 10 | 2022 | 12974 | 0.180 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2022 | 254 | 0.170 |
Why?
|
| Oximetry | 3 | 2021 | 190 | 0.170 |
Why?
|
| Ketamine | 1 | 2023 | 238 | 0.170 |
Why?
|
| Myocardial Contraction | 2 | 2017 | 289 | 0.170 |
Why?
|
| Triiodothyronine | 1 | 2019 | 82 | 0.160 |
Why?
|
| Models, Statistical | 2 | 2016 | 1184 | 0.160 |
Why?
|
| Double-Blind Method | 3 | 2018 | 2570 | 0.160 |
Why?
|
| Perioperative Care | 3 | 2023 | 448 | 0.150 |
Why?
|
| Metabolome | 1 | 2021 | 354 | 0.150 |
Why?
|
| Cardiomyopathies | 1 | 2003 | 548 | 0.150 |
Why?
|
| Adolescent | 14 | 2023 | 32687 | 0.150 |
Why?
|
| Thyroxine | 1 | 2018 | 113 | 0.150 |
Why?
|
| Odds Ratio | 3 | 2019 | 2297 | 0.150 |
Why?
|
| Quality of Life | 1 | 2012 | 4806 | 0.150 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 128 | 0.150 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 5144 | 0.150 |
Why?
|
| Precision Medicine | 2 | 2016 | 1216 | 0.150 |
Why?
|
| Acetazolamide | 1 | 2017 | 34 | 0.150 |
Why?
|
| Airway Extubation | 2 | 2023 | 73 | 0.150 |
Why?
|
| Chlorides | 1 | 2018 | 137 | 0.150 |
Why?
|
| Risk Adjustment | 1 | 2017 | 73 | 0.150 |
Why?
|
| Hospital Mortality | 5 | 2020 | 1233 | 0.140 |
Why?
|
| Biofilms | 1 | 2019 | 203 | 0.140 |
Why?
|
| Coronary Aneurysm | 1 | 1997 | 35 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2019 | 207 | 0.140 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2022 | 191 | 0.140 |
Why?
|
| Follow-Up Studies | 7 | 2017 | 15274 | 0.140 |
Why?
|
| Hypokalemia | 1 | 2017 | 61 | 0.140 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 215 | 0.140 |
Why?
|
| Prognosis | 9 | 2018 | 22527 | 0.140 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 2018 | 98 | 0.140 |
Why?
|
| Infant, Premature, Diseases | 1 | 2019 | 256 | 0.140 |
Why?
|
| Data Collection | 1 | 2019 | 601 | 0.130 |
Why?
|
| Logistic Models | 5 | 2017 | 3423 | 0.130 |
Why?
|
| Early Diagnosis | 1 | 2017 | 315 | 0.130 |
Why?
|
| Patient Selection | 1 | 2004 | 2029 | 0.130 |
Why?
|
| Asthma | 1 | 2004 | 894 | 0.130 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 363 | 0.130 |
Why?
|
| Birthing Centers | 1 | 2015 | 9 | 0.130 |
Why?
|
| ROC Curve | 3 | 2017 | 1250 | 0.130 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2017 | 207 | 0.130 |
Why?
|
| Hyperkalemia | 1 | 2017 | 79 | 0.130 |
Why?
|
| Ventilators, Mechanical | 1 | 2016 | 46 | 0.130 |
Why?
|
| Injections, Intravenous | 1 | 2016 | 590 | 0.130 |
Why?
|
| Case-Control Studies | 8 | 2018 | 6231 | 0.130 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2017 | 164 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 252 | 0.130 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2017 | 169 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2003 | 878 | 0.130 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 380 | 0.130 |
Why?
|
| Acute Disease | 5 | 2018 | 2491 | 0.120 |
Why?
|
| Body Fluids | 1 | 2016 | 121 | 0.120 |
Why?
|
| Health Personnel | 2 | 2023 | 650 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2017 | 9450 | 0.120 |
Why?
|
| Patient Admission | 2 | 2014 | 231 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2003 | 1154 | 0.120 |
Why?
|
| Resuscitation | 1 | 2017 | 268 | 0.120 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 2017 | 262 | 0.120 |
Why?
|
| Tertiary Care Centers | 2 | 2014 | 419 | 0.120 |
Why?
|
| Administration, Inhalation | 2 | 2014 | 299 | 0.120 |
Why?
|
| Bacteria | 1 | 2019 | 650 | 0.120 |
Why?
|
| Hospital Costs | 1 | 2016 | 244 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2022 | 623 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2022 | 701 | 0.120 |
Why?
|
| Patient Readmission | 2 | 2020 | 571 | 0.110 |
Why?
|
| Bradycardia | 1 | 2014 | 72 | 0.110 |
Why?
|
| Water-Electrolyte Balance | 1 | 2014 | 99 | 0.110 |
Why?
|
| Cardiology | 3 | 2016 | 512 | 0.110 |
Why?
|
| Coronary Disease | 1 | 1997 | 741 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 1301 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 256 | 0.110 |
Why?
|
| gamma-Linolenic Acid | 1 | 2013 | 3 | 0.110 |
Why?
|
| Immunization, Passive | 1 | 2013 | 179 | 0.110 |
Why?
|
| Missouri | 1 | 2012 | 41 | 0.110 |
Why?
|
| Gases | 1 | 2012 | 39 | 0.110 |
Why?
|
| Predictive Value of Tests | 5 | 2014 | 4963 | 0.110 |
Why?
|
| Inappropriate Prescribing | 1 | 2013 | 54 | 0.110 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 151 | 0.110 |
Why?
|
| Pregnancy Complications | 1 | 2017 | 541 | 0.100 |
Why?
|
| Inflammation | 2 | 2020 | 2491 | 0.100 |
Why?
|
| Drug Overdose | 1 | 2013 | 97 | 0.100 |
Why?
|
| Endothelium-Dependent Relaxing Factors | 1 | 2012 | 5 | 0.100 |
Why?
|
| Hypoglycemia | 1 | 2014 | 221 | 0.100 |
Why?
|
| Reproducibility of Results | 6 | 2017 | 6192 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2012 | 2855 | 0.100 |
Why?
|
| Vancomycin | 1 | 2014 | 292 | 0.100 |
Why?
|
| Kidney | 2 | 2017 | 2101 | 0.100 |
Why?
|
| Acute Lung Injury | 1 | 2013 | 90 | 0.100 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2013 | 95 | 0.100 |
Why?
|
| Endocrine System Diseases | 2 | 2010 | 89 | 0.100 |
Why?
|
| Regional Blood Flow | 1 | 2012 | 277 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2016 | 592 | 0.100 |
Why?
|
| Statistics, Nonparametric | 2 | 2004 | 982 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 4468 | 0.100 |
Why?
|
| Oxygen Consumption | 2 | 2011 | 418 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 1557 | 0.090 |
Why?
|
| Heart | 1 | 2017 | 1173 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2014 | 2087 | 0.090 |
Why?
|
| Patient Care Team | 2 | 2006 | 824 | 0.090 |
Why?
|
| Cytokines | 2 | 2010 | 2803 | 0.090 |
Why?
|
| Evidence-Based Practice | 1 | 2011 | 129 | 0.090 |
Why?
|
| Enteral Nutrition | 1 | 2013 | 341 | 0.090 |
Why?
|
| Interleukins | 1 | 2012 | 339 | 0.090 |
Why?
|
| Drug Utilization Review | 2 | 2013 | 37 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2017 | 2225 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2011 | 2395 | 0.090 |
Why?
|
| Administration, Oral | 1 | 2014 | 1592 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2010 | 90 | 0.090 |
Why?
|
| Adult | 6 | 2023 | 82023 | 0.090 |
Why?
|
| Antioxidants | 1 | 2013 | 519 | 0.080 |
Why?
|
| Gene Expression | 4 | 2012 | 3606 | 0.080 |
Why?
|
| Cross Infection | 2 | 2011 | 547 | 0.080 |
Why?
|
| Reperfusion | 1 | 2009 | 25 | 0.080 |
Why?
|
| Cell Nucleus | 1 | 2014 | 1715 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2011 | 2477 | 0.080 |
Why?
|
| Gene Expression Regulation | 3 | 2015 | 4102 | 0.080 |
Why?
|
| Chi-Square Distribution | 2 | 2014 | 1306 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 5157 | 0.080 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2005 | 67 | 0.080 |
Why?
|
| RNA, Messenger | 2 | 2017 | 6344 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2011 | 709 | 0.080 |
Why?
|
| RNA | 2 | 2010 | 1057 | 0.080 |
Why?
|
| Appendicitis | 1 | 2010 | 177 | 0.080 |
Why?
|
| Recovery of Function | 2 | 2019 | 686 | 0.070 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 556 | 0.070 |
Why?
|
| Mitochondria | 1 | 2014 | 1292 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2014 | 9278 | 0.070 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 1217 | 0.070 |
Why?
|
| Child Health Services | 1 | 2007 | 88 | 0.070 |
Why?
|
| Pregnancy | 2 | 2017 | 7916 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2014 | 2346 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 9053 | 0.060 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2006 | 66 | 0.060 |
Why?
|
| Blood Group Antigens | 1 | 2006 | 76 | 0.060 |
Why?
|
| Survival Rate | 3 | 2019 | 12528 | 0.060 |
Why?
|
| Incidence | 3 | 2019 | 5814 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2003 | 1931 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2007 | 206 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2016 | 3187 | 0.060 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2006 | 128 | 0.060 |
Why?
|
| Respiratory Tract Infections | 1 | 2008 | 405 | 0.060 |
Why?
|
| Genome, Human | 2 | 2014 | 1896 | 0.060 |
Why?
|
| Confidence Intervals | 1 | 2006 | 747 | 0.060 |
Why?
|
| Infusions, Intravenous | 2 | 2017 | 1436 | 0.060 |
Why?
|
| Birth Weight | 1 | 2006 | 323 | 0.060 |
Why?
|
| Prazosin | 1 | 2003 | 23 | 0.060 |
Why?
|
| Adrenergic Agonists | 1 | 2003 | 14 | 0.060 |
Why?
|
| Cannabinoids | 1 | 2024 | 43 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2018 | 501 | 0.060 |
Why?
|
| Health Care Surveys | 1 | 2005 | 415 | 0.060 |
Why?
|
| Vasopressins | 1 | 2003 | 62 | 0.060 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2003 | 71 | 0.060 |
Why?
|
| Laryngeal Masks | 1 | 2004 | 79 | 0.060 |
Why?
|
| Creatinine | 2 | 2017 | 524 | 0.060 |
Why?
|
| Preoperative Care | 1 | 2010 | 1581 | 0.060 |
Why?
|
| Heart Massage | 1 | 2003 | 30 | 0.060 |
Why?
|
| Defibrillators, Implantable | 2 | 2004 | 227 | 0.060 |
Why?
|
| Electric Countershock | 1 | 2003 | 72 | 0.050 |
Why?
|
| Reoperation | 2 | 2018 | 1388 | 0.050 |
Why?
|
| Aging | 1 | 2011 | 1531 | 0.050 |
Why?
|
| Propranolol | 1 | 2003 | 151 | 0.050 |
Why?
|
| Tidal Volume | 1 | 2003 | 57 | 0.050 |
Why?
|
| Premature Birth | 1 | 2007 | 375 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2003 | 165 | 0.050 |
Why?
|
| Peer Review, Research | 1 | 2023 | 66 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 455 | 0.050 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2003 | 59 | 0.050 |
Why?
|
| Ventricular Function, Left | 1 | 2006 | 563 | 0.050 |
Why?
|
| Peer Group | 1 | 2023 | 141 | 0.050 |
Why?
|
| Calcium Chloride | 1 | 2021 | 25 | 0.050 |
Why?
|
| Aorta | 1 | 2006 | 666 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2023 | 211 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2020 | 2656 | 0.050 |
Why?
|
| Guidelines as Topic | 2 | 2018 | 359 | 0.050 |
Why?
|
| Young Adult | 2 | 2017 | 22238 | 0.050 |
Why?
|
| Comorbidity | 2 | 2020 | 2393 | 0.050 |
Why?
|
| Mentors | 1 | 2023 | 209 | 0.050 |
Why?
|
| Genomics | 2 | 2010 | 2831 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 336 | 0.050 |
Why?
|
| Myocardial Stunning | 1 | 2000 | 21 | 0.040 |
Why?
|
| Myofibrils | 1 | 2000 | 26 | 0.040 |
Why?
|
| Cooperative Behavior | 2 | 2016 | 306 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2003 | 550 | 0.040 |
Why?
|
| Endocardium | 1 | 2000 | 51 | 0.040 |
Why?
|
| Cardiovascular System | 1 | 2022 | 142 | 0.040 |
Why?
|
| Morphine | 1 | 2022 | 331 | 0.040 |
Why?
|
| Methadone | 1 | 2022 | 213 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2010 | 3840 | 0.040 |
Why?
|
| Skin Temperature | 1 | 2019 | 33 | 0.040 |
Why?
|
| Swine | 1 | 2003 | 1513 | 0.040 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 1064 | 0.040 |
Why?
|
| North America | 1 | 2020 | 337 | 0.040 |
Why?
|
| Brain | 1 | 2012 | 4198 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2003 | 2313 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 249 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 100 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2015 | 2360 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 853 | 0.040 |
Why?
|
| Leukocytes | 2 | 2011 | 420 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2018 | 141 | 0.040 |
Why?
|
| Animals | 4 | 2024 | 61340 | 0.040 |
Why?
|
| Oliguria | 1 | 2017 | 20 | 0.040 |
Why?
|
| Electrocardiography | 1 | 2003 | 1144 | 0.040 |
Why?
|
| Chemokines, CC | 1 | 2016 | 38 | 0.030 |
Why?
|
| Community-Acquired Infections | 1 | 2019 | 286 | 0.030 |
Why?
|
| Adenosine | 1 | 2018 | 293 | 0.030 |
Why?
|
| Standard of Care | 1 | 2018 | 277 | 0.030 |
Why?
|
| Community Participation | 1 | 2016 | 53 | 0.030 |
Why?
|
| Platelet Count | 1 | 2016 | 488 | 0.030 |
Why?
|
| Immunization | 1 | 2017 | 383 | 0.030 |
Why?
|
| Mathematical Computing | 1 | 2015 | 23 | 0.030 |
Why?
|
| Myeloblastin | 1 | 2015 | 65 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2018 | 489 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 180 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2017 | 748 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2015 | 198 | 0.030 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2016 | 172 | 0.030 |
Why?
|
| Signal Transduction | 4 | 2015 | 12033 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 245 | 0.030 |
Why?
|
| Heat-Shock Response | 1 | 2014 | 41 | 0.030 |
Why?
|
| Medicine | 1 | 2016 | 134 | 0.030 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 271 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 1073 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 731 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 417 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 2180 | 0.030 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2013 | 4 | 0.030 |
Why?
|
| Drug Dosage Calculations | 1 | 2013 | 46 | 0.030 |
Why?
|
| Wounds and Injuries | 1 | 2017 | 424 | 0.030 |
Why?
|
| Food, Formulated | 1 | 2013 | 55 | 0.030 |
Why?
|
| Pandemics | 1 | 2022 | 1607 | 0.030 |
Why?
|
| Arachidonic Acid | 1 | 2013 | 120 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2014 | 726 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2014 | 757 | 0.030 |
Why?
|
| Gestational Age | 1 | 2016 | 1160 | 0.030 |
Why?
|
| Registries | 1 | 2020 | 2208 | 0.020 |
Why?
|
| Calcitonin | 1 | 2012 | 182 | 0.020 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2012 | 168 | 0.020 |
Why?
|
| Mortality | 1 | 2014 | 347 | 0.020 |
Why?
|
| Family | 1 | 2016 | 782 | 0.020 |
Why?
|
| Aged | 1 | 2017 | 73579 | 0.020 |
Why?
|
| Leukocyte Elastase | 1 | 2011 | 71 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2012 | 396 | 0.020 |
Why?
|
| Risk | 1 | 2015 | 1929 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2016 | 871 | 0.020 |
Why?
|
| Protein Precursors | 1 | 2012 | 251 | 0.020 |
Why?
|
| Immunomodulation | 1 | 2013 | 253 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2016 | 696 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2017 | 3534 | 0.020 |
Why?
|
| Child Mortality | 1 | 2010 | 22 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 678 | 0.020 |
Why?
|
| Electrophoresis | 1 | 2010 | 74 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2003 | 7317 | 0.020 |
Why?
|
| Health | 1 | 2010 | 51 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2011 | 286 | 0.020 |
Why?
|
| Publications | 1 | 2010 | 54 | 0.020 |
Why?
|
| Heart Block | 1 | 2010 | 45 | 0.020 |
Why?
|
| Nutrition Therapy | 1 | 2010 | 23 | 0.020 |
Why?
|
| Energy Intake | 1 | 2013 | 516 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 432 | 0.020 |
Why?
|
| Chylothorax | 1 | 2010 | 42 | 0.020 |
Why?
|
| Technology | 1 | 2010 | 100 | 0.020 |
Why?
|
| Research Report | 1 | 2010 | 135 | 0.020 |
Why?
|
| Respiratory Tract Diseases | 1 | 2010 | 111 | 0.020 |
Why?
|
| Blood Cells | 1 | 2009 | 127 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 503 | 0.020 |
Why?
|
| Genotype | 1 | 2017 | 4245 | 0.020 |
Why?
|
| Parents | 1 | 2016 | 1083 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2011 | 479 | 0.020 |
Why?
|
| Body Weight | 1 | 2013 | 1282 | 0.020 |
Why?
|
| Blood Cell Count | 1 | 2008 | 233 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 5093 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4493 | 0.020 |
Why?
|
| Pregnancy, High-Risk | 1 | 2007 | 48 | 0.020 |
Why?
|
| Mice | 1 | 2008 | 35414 | 0.020 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2007 | 39 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 481 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2009 | 1076 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2005 | 121 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2007 | 186 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 2010 | 616 | 0.020 |
Why?
|
| Elapid Venoms | 1 | 2004 | 11 | 0.010 |
Why?
|
| Kidney Diseases | 1 | 2010 | 678 | 0.010 |
Why?
|
| Infant Welfare | 1 | 2004 | 28 | 0.010 |
Why?
|
| Ultrafiltration | 1 | 2004 | 25 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2008 | 758 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2008 | 1161 | 0.010 |
Why?
|
| Phenotype | 1 | 2015 | 6502 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 448 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 2412 | 0.010 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2004 | 657 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 4837 | 0.010 |
Why?
|
| Sarcomeres | 1 | 2000 | 30 | 0.010 |
Why?
|
| Crystallins | 1 | 2000 | 30 | 0.010 |
Why?
|
| Creatine Kinase | 1 | 2000 | 93 | 0.010 |
Why?
|
| Myosins | 1 | 2000 | 95 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 2000 | 105 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2000 | 205 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2000 | 437 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2004 | 1824 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2000 | 697 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2017 | 7055 | 0.010 |
Why?
|
| Peptides | 1 | 2004 | 1502 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2000 | 327 | 0.010 |
Why?
|
| Dogs | 1 | 2000 | 1082 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 3903 | 0.010 |
Why?
|
| Neoplasms | 1 | 2017 | 15949 | 0.010 |
Why?
|
| Apoptosis | 1 | 2000 | 7755 | 0.000 |
Why?
|